Aptevo Therapeutics Inc. (NASDAQ: APVO) today announced that new preclinical data on the Company’s next generation bispecific antibody candidate, APVO436 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE